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ABSTRACT In mammals, hypoxia-triggered erythro-
poietin release increases red blood cellmass tomeet tissue
oxygen demands. Using male Wistar rats, we unmask
a previously unrecognized regulatory pathway of erythro-
poiesis involving suppressor control by the NOmetabolite
and ubiquitous dietary component nitrate. We ﬁnd that
circulating hemoglobin levels are modulated by nitrate at
concentrations achievable by dietary intervention under
normoxic and hypoxic conditions; a moderate dose of ni-
trate administered via the drinkingwater (7mgNaNO3/kg
body weight/d) lowered hemoglobin concentration and
hematocrit after 6 d compared with nonsupplemented/
NaCl-supplemented controls. The underlying mechanism
is suppression of hepatic erythropoietin expression asso-
ciated with the downregulation of tissue hypoxia markers,
suggesting increased pO2. At higher nitrate doses, how-
ever, a partial reversal of this effect occurred; this was
accompaniedby increased renal erythropoietin expression
and stabilization of hypoxia-inducible factors, likely
brought about by the relative anemia. Thus, hepatic and
renal hypoxia-sensing pathways act in concert to modulate
hemoglobin in response to nitrate, converging at an opti-
malminimal hemoglobin concentration appropriate to the
environmental/physiologic situation. Suppression of he-
patic erythropoietin expression by nitrate may thus act to
decrease blood viscosity while matching oxygen supply to
demand, whereas renal oxygen sensing could act as
a brake, averting a potentially detrimental fall in hema-
tocrit.—Ashmore, T., Fernandez, B. O., Evans, C. E.,
Huang, Y., Branco-Price, C., Grifﬁn, J. L., Johnson, R. S.,
Feelisch, M., Murray, A. J. Suppression of erythropoi-
esis by dietary nitrate. FASEB J. 29, 1102–1112 (2015).
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OXYGEN HOMEOSTASIS IS CRITICAL for proper organ function
and survival of mammals. By means of hemoglobin (Hb)-
containing red cell production (erythropoiesis) and blood
ﬂow regulation, oxygen supply is matched to tissue oxygen
demand. In response todecreasedcellularoxygen tensions
(pO2), regionsof thekidneys (1, 2) and the liver (3) release
the hormone erythropoietin (EPO) (4), stimulating
erythropoiesis and mitigating a fall in oxygen transport.
Although the majority of EPO is derived from the kidneys
(3), hepatic EPOproductionmay account for one-third of
total EPO under conditions of severe hypoxia (5). EPO
expression in these tissues is under the control of the
hypoxia-inducible factor 2 (HIF2) (6–8); this transcription
factor is constitutively expressed and continuously de-
graded in normoxia, yet becomes stabilized under con-
ditions of severe/prolonged hypoxia, e.g., during an
extended sojourn to high altitude. As such, with sufﬁcient
time to acclimate, oxygen content ismaintainedat sea level
values in mountaineers even up to 7000 m above sea level,
with increased blood Hb content compensating for de-
creased arterial Hb-O2 saturation (9).
With prolonged/severe hypoxia, however—a condition
prevalent in critical illness andunavoidable at high altitude
(10)—an elevated hematocrit can lead to a detrimental
increase in blood viscosity (e.g., in chronic obstructive
pulmonary disease and Monge’s disease) (11), which may
impair blood ﬂow through the microcirculation (12). An
increased hematocrit may not, therefore, substantially in-
crease oxygen delivery when pO2 and oxygen saturation
are low. In support of this notion, VO2max remains low at
high altitude, even in fully acclimatized subjects (13); of
note, Tibetan natives, adapted to life at high altitude for
generations, do not have the elevated hematocrit of
altitude-acclimatized lowland natives (14, 15), an adapta-
tion associated with enhanced forearm blood ﬂow and
elevated plasma nitrogen oxide levels (16).
Nitrate (NO3
2), the metabolic end product of the sig-
naling molecule NO and a ubiquitous dietary constituent,
lowers the oxygen cost of exercise by improving mitochon-
drial efﬁciency (17). Nitrate may also be an alternative
sourceofNO,particularlywhenoxygenavailability is limited
(18). A possible role of NO in the control of red blood cell
development via effects on erythroid cells, has been
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suggested (19), whereas in a study using eNOS knockout
mice and NOS inhibitors, endogenous NO was found to
attenuate renal EPO expression in mice (20). We hypoth-
esized that nitrate administration, via the diet, might limit
hematocrit rises inoverthypoxiaby improving theefﬁciency
of oxygen utilization, thereby decreasing the amount of Hb
needed for oxygen delivery. We set out to investigate the
effects of dietary nitrate on circulatingHb in rats exposed to
environmental hypoxia and found that under both hypoxic
and normoxic conditions, a moderate dose of nitrate com-
parable to that known to enhancemitochondrial efﬁciency
in humans (17), suppresses plasma EPO levels and lowers
circulating Hb concentrations. We subsequently inves-
tigated the mechanisms underpinning these effects of ni-
trate and found that both liver and kidneys are involved
in optimizing hematocrit in relation to environmental
conditions and circulating nitrate concentrations.
MATERIALS AND METHODS
All procedures were carried out by a license holder in accordance
with UK Home Ofﬁce regulations under the Animals in Scien-
tiﬁc Procedures Act and were reviewed by the University of
Cambridge Animal Welfare and Ethical Review Committee.
Hypoxia study
Male Wistar rats (2736 2 g; n = 40) were acquired from Charles
River (Margate, United Kingdom) and maintained on a stan-
dardized quality-controlled chow to normalize micronutrient
levels [RM1(E)SQC; Special Diets Services, Essex, United
Kingdom; 55% carbohydrate, 3% fat, 15% protein). The
hypoxia/nitrate protocol was as previously described (21). Af-
ter a 12 d acclimatization, animals received either 0.7 mM
NaNO3 (nitrate group) or NaCl (control group, matched for
salinity and sodium content; both ultra-pure; Sigma-Aldrich,
Dorset, United Kingdom) in distilled water (n = 20/group).
After 4 d, half of each group was transferred to hypoxia cham-
bers at 13%O2 with 20 air changes/h (PFI Systems Ltd., Milton
Keynes, United Kingdom; n = 10/group). All animals remained
in these conditions, with ad libitum access to food andNaNO3 or
NaCl-supplemented water, for 14 d. Animals were housed
pairwise in conventional cages at controlled humidity and
temperature with a normal 12 h/12 h light/dark cycle. Food
and water consumptions were monitored daily, and nitrate
intakes were calculated from measured nitrate contents.
Time course and dose-response studies
To investigate the time course of the effect of nitrate supple-
mentation, rats (2676 3 g; n = 24) were housed under normoxia
and conditions otherwise identical to those above, on standard-
ized rodent chow, with access to distilled water ad libitum. After
12 d, the drinking water was supplemented with 0.7 mM NaNO3
withmeasurements taken after 0, 2, 4, 6, 9, and 12 d (n = 4/group).
Toestablish thedose-response relationship,maleWistar rats (2696
2 g; n = 24) were also kept under normoxic conditions and on
standardized rodent chow as above, with access to distilled water
ad libitum. After a 12 d acclimatization, rats received distilled water
or water supplemented with NaNO3 (0.35, 0.7, 1.4 mM; n = 6/
group) ad libitum for a further 18 d.
Hemoglobin, hematocrit, and erythropoietin
On killing, blood was collected by cardiac puncture. Hb con-
centration was measured by an automated analyzer (HemoCue
Hb 201; A¨ngelholm, Sweden). Hematocrit was determined by
measurement of packed cell volume after centrifugation of fresh
blood in heparinized capillary tubes. EPO concentrations in
plasma were determined using a commercial ELISA assay (Rat
EPO ELISA kit; Biorbyt, Cambridge, United Kingdom).
Nitrate, nitrite, nitroso-compounds, and osmolality
Nitrate was quantiﬁed using a dedicated HPLC system (ENO-20;
Eicom, Tokyo, Japan), using sequential ion chromatography,
online reduction to nitrite using a cadmium column, and post-
columnderivatizationwith amodiﬁedGriess reagent, as described
earlier (22). Drinking water samples were analyzed directly after
dilution with ultrapure water, rodent chow after homogenization
and extraction with water, and plasma samples following depro-
teinization with 50%methanol. The concentration of total nitroso
products in plasma was quantiﬁed using triiodide-mediated re-
duction andgas phase chemiluminescencedetectionof generated
NO, as described in detail elsewhere (22). Plasma osmolality was
determinedby freezingpointdepressionusingamicro-osmometer
(Model 3320; Advanced Instruments, Norwood, MA, USA).
Arterial oxygen saturation
In vivo Hb-O2 saturations were determined by pulse oximetry
at d 0 and 10 of the dose-response study using aMouseOx System
(STARR Life Sciences Corporation, Oakmont, PA, USA). Ani-
malswere allowed to acclimatize, andmeasurements were taken
after 30 min of constant readings.
Gene expression analysis
Total RNA was puriﬁed from crushed, frozen liver and kidney
using an RNeasy Mini Kit (QIAgen, Germantown, MD, USA).
RNA concentration was quantiﬁed at 260 nm using a Smart-
SpecPlus spectrophotometer (Bio-Rad).
For analysis of steady-state mRNA levels, relative abundance of
transcripts of interest was assessed by quantitative PCR in SYBR
Green FastStart Universal Master Mix (Applied Biosystems,
Grand Island, NY, USA) with a StepOnePlus detection system
(AppliedBiosystems).QuantiTect primer assays for ratEpo, Vegfa,
Pgk1, Slc1a2, Ca9, and Nos2 were obtained from QIAgen. Ex-
pression levelswerenormalized toActbusing theΔCTmethodand
subsequently to the “normoxia/chloride” group in the hypoxia
study and to the “control” group in the dose-response study to
express as fold changes.
Immunohistochemistry
Transverse parafﬁn-embedded kidney sections (7 mm) were
immunostained for HIF1a as described (23) with primary anti-
body binding detected using biotinylated rabbit anti-mouse
(Dako, Carpinteria, CA, USA). Contiguous sections were also
immunostained for HIF2a by replacing the anti-HIF1a antibody
with an anti-HIF2a antibody (Novus Biologicals, Cambridge,
United Kingdom). Isotype-matched IgG was used as a negative
control. Images of immunostained sections were captured in
a blinded fashion using a light microscope and mounted camera
(M165FC and DFC310FX; Leica, Newcastle upon Tyne, United
Kingdom). Positive staining was quantiﬁed as previously de-
scribed (24, 25) and expressed as average percentage of trans-
verse tissue area throughout the length of the tissue.
Statistics
Results are expressed as mean 6 SEM. ANOVA was used to de-
termine signiﬁcant differences across the 4 groups of the hypoxia
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and dose-response studies and 6 groups of the time course study.
Dunnett’s post hoc analyses provided signiﬁcance levels between
groups compared to normoxia/NaCl controls in the hypoxia
study, untreated controls in the dose-response study, and d 0
controls in the time course study. A 2-tailed nonparametric
Pearson correlation was used to determine Hb and EPO corre-
lations in the dose-response and time course studies. Differences
were considered signiﬁcant when P, 0.05.
RESULTS
Hypoxia study
We ﬁrst investigated the effects of a moderate dose of di-
etary nitrate on circulating Hb in normoxic and hypoxia-
exposed rats.
Neither hypoxic exposure nor nitrate supplementation
altered food or water intake; thus, all groups had identical
calorie intakes (Table 1). Calculateddietary nitrate intakes
amounted to 16 0 (normoxia/NaCl), 96 0 (normoxia/
NaNO3), 1 6 0 (hypoxia/NaCl), and 7 6 0 (hypoxia/
NaNO3) mg NaNO3/kg body weight/d. There were no
signiﬁcant differences in starting or ﬁnal body weights
between groups; however, ﬁnal body weights tended to be
lower in hypoxic rats, whether supplemented with nitrate
or chloride (Table 1).
Plasma nitrate concentrations were the same in nor-
moxic and hypoxic NaCl-supplemented rats; however, di-
etarynitrate supplementation innormoxicandhypoxic rats
resulted in plasma nitrate levels that were 80% (P, 0.001)
and 35% (P, 0.05) greater than those in normoxia/NaCl
rats (Table 1). With this dose of dietary nitrate, no differ-
ences in either circulating nitrite or nitroso-compound
concentrations were observed (Table 1).
As anticipated, circulating Hb concentrations were 20%
higher in hypoxia/NaCl rats compared with normoxia/
NaCl rats (P, 0.01). Nitrate supplementation of hypoxic
rats, however, resulted in Hb concentrations that were in-
termediate between those of hypoxia/NaCl rats and
normoxia/NaCl rats. Unexpectedly, Hb concentrations of
nitrate-supplemented normoxic rats were also lower than
those in normoxia/NaCl rats by 15% (P, 0.05; Fig. 1A).
To understand whether the observed Hb-lowering
effects of nitrate were associated with alterations in EPO
production and/or secretion, plasma EPO levels and Epo
expression in liver and kidney were measured. Following
hypoxic exposure, plasma EPO levels reﬂected circulating
Hb levels, being 18% higher in hypoxia/NaCl rats than in
normoxia/NaCl rats (P , 0.01; Fig. 1B). Meanwhile, ni-
trate supplementation, in normoxic and hypoxic rats,
resulted in plasma EPO levels that were 72% (P , 0.001)
and 46% (P, 0.001) lower than those of normoxia/NaCl
rats (Fig. 1B).
Across the 4 experimental groups, hepatic Epo expres-
sion reﬂected circulatingEPOlevels, withEpomRNAbeing
70% higher in the livers of hypoxia/NaCl rats compared
with those of normoxia/NaCl rats (P, 0.001; Fig. 1C). Epo
mRNA levels were 71% lower in the livers of normoxia/
NaNO3 rats compared with normoxia/NaCl rats (P ,
0.01) and 53% lower in the same organ when comparing
nitrateandchloride-supplementedgroups inhypoxia (P,
0.001; Fig. 1C). In contrast, however, levels of renal Epo
mRNA were not signiﬁcantly higher in hypoxia/NaCl rats
than in normoxia/NaCl rats (Fig. 1D), whereas EpomRNA
was 56% (P , 0.05) and 67% (P , 0.05) higher in the
kidneys of normoxia/NaNO3 and hypoxia/NaNO3, re-
spectively, than in those of normoxia/NaCl rats (Fig. 1D).
At this stage, ourdata suggested that the effects of nitrate
were mediated via changes in hepatic Epo expression, al-
tering circulating EPO levels. Meanwhile, the elevation of
Epo expression by nitrate in the kidneys, which was exac-
erbated by environmental hypoxia, is consistent with the
notion of enhanced renal hypoxia secondary to dimin-
ished oxygen delivery as a result of relative anemia.
Time course study
Next, we investigated the time course of the effect of the
samemoderate level of dietary nitrate supplementation on
circulatingHb levels in a separate groupof ratsmaintained
under normoxia.
Over 12 d of nitrate supplementation, food intake and
water intake was not altered (data not shown); nitrate
TABLE 1. Effects of 18 d supplementation with 0.7 mM nitrate on food, water, and nitrate intake, body
weight, and plasma nitrogen oxide levels in normoxic and hypoxic rats (13% O2)
Parameter
Normoxia Hypoxia
NaCl NaNO3 NaCl NaNO3
Intake levels
Food (g/d) 32 6 2 33 6 1 35 6 2 33 6 1
Water (ml/d) 28 6 1 38 6 10 37 6 4 32 6 2
Nitrate (mg/kg/d) 1 6 0 9 6 0* 1 6 0 7 6 0†
Body weights
Start (g) 268 6 5 268 6 6 276 6 2 280 6 4
End (g) 429 6 8 431 6 9 416 6 14 412 6 12
Plasma NO levels
Nitrate (mM) 7.1 6 1.0 12.8 6 1.1* 5.0 6 0.5 9.6 6 0.6†
Nitrite (mM) 0.5 6 0.1 0.4 6 0.1 0.5 6 0.0 0.6 6 0.1
Nitroso-compounds (nM) 13.3 6 0.9 14.7 6 3.0 19.6 6 4.9 12.6 6 1.7
n = 8–10 per group. *P, 0.001 compared with normoxia/NaCl. †P, 0.001 compared with hypoxia/
NaCl.
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intake amounted to 9 mg/kg body weight/d, consistent
with the earlier hypoxia study. This level of nitrate sup-
plementation elevated plasma nitrate levels 2.2-fold to
24.86 4.2 mM from d 2 onward (Fig. 2A), with no signiﬁ-
cant effect on plasma nitrite or nitroso levels (Supple-
mental Fig. 1A, B) and osmolality (Supplemental Fig. 1C).
This level of nitrate supplementation resulted in a time-
dependent fall in circulating Hb concentration and
hematocrit (Fig. 2B, C), which reached signiﬁcance by d 6
and 9, respectively, and remained lower for the remainder
of the study. Furthermore, plasma EPO concentrations
similarly fell in a time-dependent manner, reaching signif-
icance at d 6 (Fig. 2D).
Dose-response study
To understand the dose dependence of the nitrate effects
on circulating Hb, we carried out a dose-response study in
which a further group of rats were supplemented with
0 mM (control), 0.35 mM (low dose), 0.7 mM (medium
dose), or 1.4 mM (high dose) NaNO3 in their drinking
water for 18 d. The medium dose corresponded to that
used in the previous 2 studies and is essentially a repeat of
the normoxia/NaNO3 group in the hypoxia study. Nitrate
intakes amounted to 1.2 6 0.1, 4.2 6 0.1, 7.0 6 0.4, and
12.1 6 0.6 mg NaNO3/kg body weight/d in control, low
dose,mediumdose, andhighdosegroups, respectively.No
dose of NaNO3 had any effect on growth, food intake, or
water intake (Table 2).
Circulating plasma nitrate levels were dose-dependently
increased on nitrate supplementation (Fig. 3A). In the
medium and high dose groups, nitrate supplementation
resulted in circulating nitrate levels that were 2.1-fold (P,
0.05) and 2.9-fold (P , 0.001) higher than in controls.
Plasma nitrite was not elevated in the low or medium dose
groups, but was 1.8-fold (P, 0.01) higher in the high dose
group compared with controls (Fig. 3B). Finally, circulat-
ing nitroso species were not signiﬁcantly different across
the 4 groups, although they trended upward as dose in-
creased (Supplemental Fig. 2A). Nodose of nitrate altered
plasma osmolality (Supplemental Fig. 2B) or serum total
protein concentration (Supplemental Fig. 2C).
In agreement with the hypoxia study, the medium dose
of nitratewas associatedwith 20% lowerHbconcentration,
compared with controls, whereas the low dose resulted in
a Hb concentration that was lower than controls but did
not reach signiﬁcance (Fig. 3C). Interestingly, at the high
dose of nitrate supplementation, the anemic response was
partially reversed (Fig. 3C). Arterial Hb-O2 saturation was
not affected by nitrate (Supplemental Fig. 2D).
Plasma EPO levels reﬂected circulating Hb concen-
trations in these groups, being 24% (P, 0.01), 52% (P,
0.001), and 18% (P, 0.05) lower in the low,medium, and
high dose groups, respectively, compared with controls
(Fig. 3D).
At the tissue level, hepatic Epo mRNA levels were the
same in the low dose group as in controls, but were 58%
and 55% lower in the medium and high dose rats, re-
spectively, compared with controls (P , 0.01; Fig. 3E).
Meanwhile, levels of renal Epo mRNA in the low and me-
dium dose groups were not signiﬁcantly different from
controls, but were 110% higher with high nitrate com-
pared with controls (P, 0.01; Fig. 3F). These ﬁndings are
consistent with the notion that nitrate lowers hepatic Epo
expression, lowering EPO plasma levels, whereas renal
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hypoxia is exacerbated by excess anemia, resulting in ele-
vated Epo expression at higher levels of nitrate.
In controls, Epo mRNA levels were 2-fold greater in
whole kidney homogenates compared with liver (Fig. 3G).
Across both the time course and dose-response studies,
circulating Hb concentrations correlated positively with
plasma EPO (r2 = 0.54; P, 0.001; Fig. 3H).
HIF signaling
To further elucidate themechanisms underlying the dose-
dependent effects of nitrate on circulating Hb and the
possible role of tissue hypoxia, we investigated HIF1a and
HIF2a expression in the kidneys of the rats in the dose-
response study, as well as HIF1 target gene expression in
the liver and kidneys of these rats.
RenalHIF1a andHIF2a staining(black)wasdetected in
control and nitrate-treated rats (Fig. 4). Positive staining
for HIF1a and HIF2a was observed in nucleated cell-
populated regions and appeared to be associated with cell
nuclei (red) (Fig. 4A, B). Contiguous sections exposed to
isotype-matched IgG did not stain positively (Fig. 4A, B).
HIF1a staining also appeared to be stronger than HIF2a
staining in all groups (Fig. 4A, B, quantiﬁed in Fig. 4C, D).
There were no differences in HIF1a or HIF2a staining
between controls and rats receiving either low or high
treatment doses (Fig. 4C, D). Although HIF1a and HIF2a
staining was 2-fold greater in rats receiving the medium
dose compared with controls, these differences did not
reach statistical signiﬁcance (HIF1a: 296 8 vs. 146 4% in
controls, P = 0.066; Fig. 4C; HIF2a: 4 6 2 vs. 2 6 1% in
controls, P = 0.29; Fig. 4D).
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Figure 2. Time course of Hb suppression by dietary nitrate. A) Plasma nitrate levels over 12 d of nitrate supplementation. B)
Circulating Hb levels over 12 d of nitrate supplementation. C) Hematocrit levels over 12 d of nitrate supplementation. D) Plasma
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TABLE 2. Effects of 18 d supplementation with low (0.35 mM), medium (0.7 mM), and high (1.4 mM)
doses of dietary nitrate on food, water, and nitrate intake, body weight, and plasma NO levels in rats
Parameter Control Low Medium High
Intake levels
Food intake (g/d) 32 6 1 32 6 1 31 6 0 32 6 1
Water intake (ml/d) 41 6 5 35 6 3 37 6 4 32 6 2
Nitrate intake (mg/kg/d) 1 6 0 4 6 0* 7 6 0* 12 6 1*
Body weights
Start (g) 263 6 2 271 6 4 262 6 4 281 6 3
End (g) 431 6 18 434 6 17 405 6 9 414 6 22
n = 5–6 per group. *P , 0.001 compared with control rats.
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In the liver, levels of Pgk1 and Slc2a1 (HIF1 targets) were
the same in all groups; however, levels of Vegfa, Ca9, and
Nos2 (HIF1 targets) were all dose-dependently decreased
by nitrate supplementation (Fig. 5), further supporting an
effect of nitrate on suppression of HIF signaling in this
organ. By contrast, in whole kidney homogenates, no
changes were observed in the levels of any HIF1 targets
measured in response to any dose of nitrate supplemen-
tation (Fig. 6).
DISCUSSION
Here we report that suppressor control by the NO me-
tabolite and ubiquitous dietary component, nitrate, on the
production of hepatic erythropoietin can act to lower cir-
culating Hb. As expected, environmental hypoxia in-
creased circulating Hb in rats; however, moderate nitrate
supplementation largely prevented this rise. Moreover,
nitrate decreased Hb in normoxic rats. This result, to-
gether with an observed inverse association between ni-
trate and Hb in human blood (13), suggests that nitrate
impacts on erythropoiesis even in normoxia.
NaNO3causeda time-dependentdecrease in circulating
Hb, EPO, and hematocrit, reaching signiﬁcance after d 6.
This time course of events is distinct from nitrate’s more
acute effects on mitochondrial respiration during an ex-
ercise challenge (17) or ischemic insult and consistent
with a suppression of EPO-mediated erythropoiesis. In-
terestingly, however, the intermediate nitrate dose tested
caused the maximal fall in Hb, with the anemic response
partially reversedon supplementationwith1.4mMNaNO3.
No level of nitrate supplementation tested changed osmo-
lality or plasma protein concentration. Changes in circu-
lating EPO mirrored those of Hb, suggesting an effect on
tissue oxygen sensing.
In agreement with this notion, above a threshold plasma
concentration of;20 mM, nitrate mediated a suppression
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of hepatic Epo expression with a concomitant fall in HIF1
target expression, suggesting increasedhepatic pO2, either
due to a suppression of tissue oxygen demand, perhaps via
mitochondrial action (17), or an improvement in oxygen
delivery (16). The partial reversal of this effect at higher
levels of nitrate was associated with increased renal Epo
expression, possibly as a result of renal hypoxia due to the
relative anemia brought about by nitrate’s effects on he-
paticEpo. Indeed, acute anemiahasbeen shown to stabilize
renalHIF1 andHIF2 inmice,whilst renal EPOproduction
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Figure 4. Localization and quantiﬁcation of HIF1a and HIF2a in kidneys of nitrate-treated rats. A) HIF1a and B) HIF2a staining
(black) with nucleated cells (red) in the kidney of treated rats and controls. Images are representative (.3 kidney sections/rat,
n = 4–6/group). Scale bars are 2 mm and 50 mm in left and right columns, respectively. C) Quantiﬁcation of HIF1a and (D)
HIF2a staining in the kidney of treated rats and controls (n = 4–6/group). Increases in HIF1a and HIF2a staining between
controls and rats receiving the medium treatment dose did not reach statistical signiﬁcance (P = 0.066 and P = 0.29, respectively).
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increases exponentially on hemodilution (26). In agree-
ment, at the medium dose of nitrate used in the present
study, at which Hb concentrations were lowest, we ob-
served greater expression of HIF1a and HIF2a in the
kidney; however, renal HIF levels were normalized in rats
treated with the higher dose of nitrate, when the relative
anemia was alleviated. Although we did not measure
a change in renal HIF1 target gene expression, the locali-
zation of HIF1 and HIF2 to distinct regions of the kidney
indicates the limitations associated with making these
measurements in whole tissue homogenates. Given the
elevation in plasma nitrite levels observed at the higher
dose of nitrate supplementation, it is possible that the rise
in Hb at this dose was accompanied by enhanced local
formation of methemoglobin (MetHb) via an interaction
between Hb and nitrite; however, plasma concentrations
of nitrate and nitrite, even at this highest dose, remain
below those required to induce methemoglobinemia. Al-
though it is a possible limitationof this study thatwedidnot
measureMetHb, or for that matter carboxyhemoglobin, it
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Figure 6. HIF1 target gene expression in kidneys of rats treated with dietary nitrate. A) Pgk1, (B) Slc2a1, (C) Vegfa, (D) Ca9, and (E)
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doses of dietary nitrate. Gene expression (normalized to Actb) is expressed relative to the control group.
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is unlikely that compromised oxygen delivery secondary to
focal Hb oxidation would be the sole contributor of this
reactivation of EPO production, because at the medium
dose of nitrate supplementation, which was not associated
withelevatedplasmanitrite, renalEpoexpressionandHIF2
were already increased.
The dose-response relationship indicates that this phe-
nomenon is relevant to ﬂuctuations within the physiologic
nitrate concentration range, which in humans varies with
dietary intake (primarily from green leafy vegetables) and
physical activity. Several factors other than O2, e.g., cyto-
kines, hormones including angiotensin-II (4), and oxida-
tive stress (27), are known to regulate EPO and Hb levels.
Indeed ithasbeensuggested, following studiesusingeNOS
knockout mice and NOS inhibitors, that endogenous NO
production attenuates HIF stabilization, and secondarily,
EPO transcription (20). The novelty of our ﬁndings lies in
demonstrating the effects of an endogenous metabolite
and ubiquitous dietary component, recognized as a mod-
ulator of oxygen delivery and oxygen utilization by tissues,
onpathways regulatingoxygen-carrying capacitywithin the
range of its normal physiologic concentrations. The pre-
dominant effect of nitrate would appear to be a suppres-
sion of hepatic EPO production, and although this is
thought to represent a relatively small proportion of total
EPO (;10%of total EPOproduction) (3), this proportion
might increase to ;33% during prolonged/severe hyp-
oxia (5).As such,hepaticEPOproductionwouldappear to
be particularly susceptible to ﬂuctuations in tissue oxy-
genation due to external factors. Consequently, hepatic
EPO production appears to mediate blood oxygen-
carrying capacity such that it continues to meet tissue ox-
ygen demand without excessively raising blood viscosity,
which might otherwise impair microcirculatory ﬂow and
hence tissue oxygen delivery. The renal brake on this
mechanism, as demonstratedherebyhigherdoses of nitrate
supplementation, is likely tobemediatedbyhypoxia-sensing
pathways that are activated following relative anemia, thereby
averting a detrimental fall in oxygen-carrying capacity.
Although our ﬁndings do not rule out nitrate-induced
effects onhematocrit thatmight occur downstreamofEPO
production (e.g.,onEPOsensing, erythropoiesis, or redcell
lifespan)acrossour studies,we foundacorrelationbetween
plasma EPO and blood [Hb]. As such, hepatic and renal
mechanisms appear to work in concert to optimize tissue
oxygen delivery (Fig. 7).
We and others have shown that the same dose of nitrate
(0.7 mmol/L) used here modulates oxygen consumption
across a range of tissues in rodents (21, 28) and humans
(17, 18), and thus it is seems intuitive that such a signal
might also interact with mechanisms that determine oxy-
gendelivery to the tissues in order that supply and demand
mismatches do not occur. Hematocrit is an important de-
terminant of aerobic work capacity, whereas anemia is an
independent prognostic factor in several chronic illnesses,
underlining the importance of such regulation. The reg-
ulatory mechanism we report here may also relate to the
adaptation to chronic environmental hypoxia in Tibetan
highlanders (16), who exhibit high circulating nitrate and
lowHb concentrations. Moreover, there has been a recent
resurgence of interest in the mechanisms of hepatic EPO
production (29) stimulated by the suggestion that hepatic
EPO synthesis could replace the need for recombinant
EPO administration in patients with anemia secondary to
chronic kidney disease (30). Indeed, during fetal life, the
liver rather than the kidneys is the major source of EPO,
and as such, the relevance of our ﬁndings to fetal health
would be of great interest (31). Finally, our ﬁndings offer
potential therapeutic avenues for dietary intervention in
polycythemia and other conditions warranting a reduction
in hematocrit (11).
A major strength of our study was the use of a standard-
ized quality-controlled diet and deionized water, which
allowed us to acutely manipulate micronutrient concen-
trations in rats while accurately monitoring nitrate intake.
Nitrate concentrations vary in tap water and feed, yet the
precise titration of nitrate intake achieved here, without
restricting food or water intake, allowed us to study an
effective dose response that resulted in plasma nitrate lev-
els that were tightly matched within and distinct between
Figure 7. Schematic outlining the potential mechanism underlying dose-dependent effects of dietary nitrate on renal and hepatic
erythropoietin expression (1). Nitrate supplementation enhances hepatic pO2 (2), suppressing Epo expression and thereby (3)
lowering circulating Hb (4). At higher doses of nitrate, the relative anemia resulting from hepatic effects results in renal hypoxia
(5), enhancing renal Epo expression and (6) bringing about a partial reversal in the suppression of circulating Hb levels.
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groups. Moreover, no interventions affected food (and
thus calorie) intake, which is critical because caloric re-
striction itself has been shown to suppress EPOproduction
(32, 33). The use of rats, rather than mice, as a model or-
ganismwasdeliberateas, unlikemice,NOproduction rates
(34) and circulating nitrate/nitrite concentrations (35)
are very similar to those of humans. The intermediate ni-
trate dose used here matches that used in human studies
(17) and can be readily achieved in humans via a slight
modiﬁcation of the diet. By using rats rather than mice,
however, wewereunable to capitalize on geneticmodels to
further study these mechanisms. Another strength of this
investigation is the consistency in ﬁndings across 3 in-
dependent studies and a wide range of techniques, which
has allowed us to present a comprehensive, integrated
mechanism for the control of hemoglobin by nitrate. A
possible weakness of the study, however, is that our inter-
ventions were relatively short in duration, and longer-term
studies of this effect, in rats and in humans, would be of
great interest.Moreover, the implications of theseﬁndings
for the delivery of oxygen to other tissues, during rest or
times of increased demand, e.g., acutely during an exercise
challenge or chronically during pregnancy, deserve fur-
ther attention.
Inconclusion, at levelsof intake that correspond to those
readily achievable via the diet, nitrate modulates EPO
production, suppressing hepatic Epo expression. At higher
doses of dietary nitrate, a partial reversal of this effect
occurs via increased renal Epo expression. Thus, hepatic
and renal hypoxia-sensing pathways act in concert to
modulate circulating Hb in response to nitrate supple-
mentation (and presumably other modes of variation in
circulating nitrate concentrations arising from differences
in bodily NO production). Suppression of hepatic Epo ex-
pression acts to decrease blood viscosity while matching
oxygen supply to tissue oxygen demand, whereas renal
oxygen sensing acts as a brake, averting a potentially det-
rimental fall in hematocrit.
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